Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482807 | 1.00 | LMNA (0.57) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL867222 | 1.00 | LMNA (0.57) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| Dimethylamine SCHEMBL27944752 | 0.94 | LMNA (0.52) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL11595350 | 0.85 | LMNA (0.70) | LMNAADRB1ADRB3ADRB2AOC3 | |
| SCHEMBL13849942 | 0.85 | ADRB1 (0.48) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL6690481 | 0.85 | ADRB1 (0.48) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL13849930 | 0.85 | ADRB1 (0.48) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL14402491 | 0.85 | ADRB1 (0.48) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL1154749 | 0.83 | ADRB3 (0.49) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL2879198 | 0.83 | ADRB3 (0.49) | LMNAADRB1ADRB3ADRB2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118771958-A | Preparation method of R- (+) -3-chloropropanol | 山东省药学科学院 | 2024-10-15 | — | — | CN | claimed |
| CN-112980895-B | Enzymatic synthesis method of (R) -3-chloropropanol | 宿迁阿尔法科技有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-112980895-A | Enzymatic synthesis method of (R) -3-chlorophenylpropanol | 宿迁阿尔法科技有限公司 | 2021-06-18 | — | — | CN | claimed |
| CN-121159365-A | Method for preparing high-purity R- (+) -3-chloropropanol monocyclone | 天方药业有限公司 | 2025-12-19 | — | — | CN | disclosed |
| CN-118685463-B | Dapoxetine chiral intermediates of statins enzymatic synthesis of bodies | 杭州微远生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-118879823-A | Synthesis method of (R) -3-halogenated phenylpropanol | 四川新迪生物制药有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118771958-A | Preparation method of R- (+) -3-chloropropanol | 山东省药学科学院 | 2024-10-15 | — | — | CN | disclosed |
| CN-118685463-A | Dapoxetine chiral intermediates of statins enzymatic synthesis of bodies | 杭州微远生物科技有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118666651-A | Dapoxetine chirality Process for the preparation of intermediates | 济南鸿湾生物技术有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-112980895-B | Enzymatic synthesis method of (R) -3-chloropropanol | 宿迁阿尔法科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116589367-A | Preparation method of dapoxetine hydrochloride | 济南鸿湾生物技术有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-24 | — | — | US | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| EP-1246847-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002002744-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-01-10 | — | — | WO | disclosed |
| WO-2000020386-A1 | STANNANE SYNTHESIS OF PROSTANOIDS | ALCON LABORATORIES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| EP-0743940-A1 | NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT | Astra Aktiebolag (SE) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995021821-A1 | NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT | ASTRA AKTIEBOLAG (SE) | 1995-08-17 | — | — | WO | disclosed |
| US-4918246-A | REDUCING HALOKETONE WITH DIISOPINOCAMPHEYLBORANE | ALDRICH CHEMICAL COMPANY, INC. (US) | 1990-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | LMNA 2573/4885ADRB1 468/4885ADRB3 555/4885 |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | LMNA 2573/4885ADRB1 468/4885ADRB3 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.